OncoMatch/Clinical Trials/NCT06017284
Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer
Is NCT06017284 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including Thalidomide and Nab paclitaxel for pancreatic cancer stage iv.
Treatment: Thalidomide · Nab paclitaxel · Gemcitabine — The purpose of this study is to evaluate the efficacy of thalidomide on improving the quality of life for metastatic pancreatic cancer patients receiving gemcitabine and nab-paclitaxel chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Endocrine / hormonal
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Cannot have received: anti-tumor therapy
Patients who have received any form of anti-tumor therapy.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06017284 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages